[Rosiglitazone: a clinical development focused on cardio-vascular prevention]

Related Experiment Videos

P Valensi1

  • 1Service d'Endocrinologie - Diabétologie - Nutrition, CHU Jean-Verdier, F - 93143 Bondy Cedex, France.

Annales D'Endocrinologie
|May 31, 2002
PubMed

Insights

Type 2 diabetes increases cardiovascular risk. Rosiglitazone, a thiazolidinedione, shows promise in improving vascular health and reducing atherosclerosis markers in patients with type 2 diabetes.

Area of Science:

  • Cardiovascular medicine
  • Endocrinology
  • Pharmacology

Background:

  • Type 2 diabetes is an independent cardiovascular risk factor.
  • Thiazolidinediones, including rosiglitazone, demonstrate anti-atherosclerotic effects in preclinical models.
  • Existing data suggest thiazolidinediones benefit cardiovascular parameters in type 2 diabetes patients.

Purpose of the Study:

  • To review the favorable effects of rosiglitazone and thiazolidinediones on mechanisms of atherosclerosis.
  • To summarize evidence of rosiglitazone's benefits on blood pressure, arterial wall, vasomotricity, PAI-1, and albuminuria in type 2 diabetes.
  • To justify further research into rosiglitazone's impact on cardiovascular outcomes.

Main Methods:

  • Review of in vitro and animal studies on thiazolidinediones and atherosclerosis.
  • Analysis of clinical data on rosiglitazone's effects in type 2 diabetic patients.
  • Synthesis of evidence regarding vascular, hemodynamic, and renal parameters.

Main Results:

  • Preclinical studies show rosiglitazone favorably impacts atherosclerosis mechanisms.
  • Clinical studies indicate rosiglitazone improves blood pressure and arterial properties.
  • Rosiglitazone has demonstrated positive effects on vasomotricity, PAI-1 levels, and urinary albumin excretion.

Conclusions:

  • Rosiglitazone exhibits beneficial effects on multiple cardiovascular risk factors in type 2 diabetes.
  • The observed favorable effects support the need for large-scale prospective studies.
  • Further investigation is warranted to assess rosiglitazone's impact on cardiovascular morbidity and mortality.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...